請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78229
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳林祈 | |
dc.contributor.author | Shao-Jen Wang | en |
dc.contributor.author | 王紹任 | zh_TW |
dc.date.accessioned | 2021-07-11T14:46:55Z | - |
dc.date.available | 2021-08-08 | |
dc.date.copyright | 2016-08-08 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-05 | |
dc.identifier.citation | Ahn, J. D., R. Morishita, Y. Kaneda, H. J. Kim, Y. D. Kim, H. J. Lee, K. U. Lee, J. Y. Park, Y. H. Kim, K. K. Park, Y. C. Chang, K. H. Yoon, H. S. Kwon, K. G. Park, and I. K. Lee. 2004. Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Therapy 11(11):916-923.
Aliabadi, H. M., P. Mahdipoor, and H. Uludag. 2013. Polymeric delivery of siRNA for dual silencing of Mel-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells. Cancer Gene Ther 20(3):169-177. Antunes, P., M. Ginj, H. Zhang, B. Waser, R. P. Baum, J. C. Reubi, and H. Maecke. 2007. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol I 34(7):982-993. Ashley, C. E., E. C. Carnes, G. K. Phillips, D. Padilla, P. N. Durfee, P. A. Brown, T. N. Hanna, J. W. Liu, B. Phillips, M. B. Carter, N. J. Carroll, X. M. Jiang, D. R. Dunphy, C. L. Willman, D. N. Petsev, D. G. Evans, A. N. Parikh, B. Chackerian, W. Wharton, D. S. Peabody, and C. J. Brinker. 2011. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10(5):389-397. Bae, K. H., K. Lee, J. Lee, I. S. Lee, J. H. Lee, and T. G. Park. 2011. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. J Control Release 152:E133-E134. Bae, Y. H. 2009. Drug targeting and tumor heterogeneity. J Control Release 133(1):2-3. Bagalkot, V., O. C. Farokhzad, R. Langer, and S. Jon. 2006. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Edit 45(48):8149-8152. Bagalkot, V., L. Zhang, E. Levy-Nissenbaum, S. Jon, P. W. Kantoff, R. Langer, and O. C. Farokhzad. 2007. Quantum dot - Aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer. Nano Lett 7(10):3065-3070. Baird, G. S. 2010. Where Are All the Aptamers? Am J Clin Pathol 134(4):529-531. Barton, B., T. F. Murphy, P. Shu, H. F. Huang, M. Meyenhofer, and A. Barton. 2004. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines (vol 3, pg 1183, 2004). Mol Cancer Ther 3(12):1701-1701. Bello, M. H., J. C. Mogannam, D. Morin, and L. Epstein. 2014. Endogenous ergothioneine is required for wild type levels of conidiogenesis and conidial survival but does not protect against 254 nm UV-induced mutagenesis or kill. Fungal Genet Biol 73:120-127. Bielinska, A., R. A. Shivdasani, L. Q. Zhang, and G. J. Nabel. 1990. Regulation of Gene-Expression with Double-Stranded Phosphorothioate Oligonucleotides. Science 250(4983):997-1000. Borgatti, M., D. D. Boyd, I. Lampronti, N. Bianchi, E. Fabbri, M. Saviano, A. Romanelli, C. Pedone, and R. Gambari. 2005. Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter. Oncol Res 15(7-8):373-383. Bouchard, P. R., R. M. Hutabarat, and K. M. Thompson. 2010. Discovery and Development of Therapeutic Aptamers. Annu Rev Pharmacol 50:237-257. Brown, D. A., S. H. Kang, S. M. Gryaznov, L. Dedionisio, O. Heidenreich, S. Sullivan, X. Xu, and M. I. Nerenberg. 1994. Effect of Phosphorothioate Modification of Oligodeoxynucleotides on Specific Protein-Binding. J Biol Chem 269(43):26801-26805. Buchwald, A. B., A. H. Wagner, C. Webel, and M. Hecker. 2002. Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs. J Am Coll Cardiol 39(4):732-738. Buerger, C. and B. Groner. 2003. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling. J Cancer Res Clin 129(12):669-675. Burel, S. A., S. R. Han, H. S. Lee, D. A. Norris, B. S. Lee, T. Machemer, S. Y. Park, T. Y. Zhou, G. B. He, Y. Kim, A. R. MacLeod, B. P. Monia, S. Lio, T. W. Kim, and S. P. Henry. 2013. Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys. Nucleic Acid Ther 23(3):213-227. Cao, N., D. Cheng, S. Y. Zou, H. Ai, J. M. Gao, and X. T. Shuai. 2011. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 32(8):2222-2232. Cartharius, K., K. Frech, K. Grote, B. Klocke, M. Haltmeier, A. Klingenhoff, M. Frisch, M. Bayerlein, and T. Werner. 2005. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21(13):2933-2942. Cattaruzza, M., W. Slodowski, M. Stojakovic, R. Krzesz, and M. Hecker. 2003. Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. J Biol Chem 278(39):37874-37880. Chae, Y. M., K. K. Park, I. K. Lee, J. K. Kim, C. H. Kim, and Y. C. Chang. 2006. Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction. Gene Therapy 13(5):430-439. Chae, Y. M., K. K. Park, J. Magae, I. S. Lee, C. H. Kim, H. C. Kim, S. H. Hong, J. G. Lee, I. J. Choi, H. S. Kim, K. S. Min, I. K. Lee, and Y. C. Chang. 2004. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochemical and Biophysical Research Communications 319(2):550-555. Chan, K. S., S. Sano, K. Kiguchi, J. Anders, N. Komazawa, J. Takeda, and J. DiGiovanni. 2004. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. Journal of Clinical Investigation 114(5):720-728. Charlton, J., J. Sennello, and D. Smith. 1997. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 4(11):809-816. Chen, H. J., Z. D. Yang, C. Y. Ding, L. L. Chu, Y. S. Zhang, K. Terry, H. L. Liu, Q. Shen, and J. Zhou. 2013a. Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. Acs Med Chem Lett 4(2):180-185. Chen, H. J., Z. D. Yang, C. Y. Ding, L. L. Chu, Y. S. Zhang, K. Terry, H. L. Liu, Q. Shen, and J. Zhou. 2013b. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur J Med Chem 62:498-507. Chen, R. J., Y. S. Ho, H. R. Guo, and Y. J. Wang. 2008. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 104(2):283-293. Cho, E. C., C. Glaus, J. Y. Chen, M. J. Welch, and Y. N. Xia. 2010. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med 16(12):561-573. Cho, E. J., J. W. Lee, and A. D. Ellington. 2009. Applications of Aptamers as Sensors. Annu Rev Anal Chem 2:241-264. Choudhury, N. N. and H. X. He. 2012. Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs. Curr Pharm Biotechno 13(7):1317-1331. Cole, A. J., V. C. Yang, and A. E. David. 2011. Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol 29(7):323-332. Conrad, R. C., S. Baskerville, and A. D. Ellington. 1995. In vitro selection methodologies to probe RNA function and structure. Mol Divers 1(1):69-78. Conte, M. S., D. F. Bandyk, A. W. Clowes, G. L. Moneta, L. Seely, T. J. Lorenz, H. Namini, A. D. Hamdan, S. P. Roddy, M. Belkin, S. A. Berceli, R. J. DeMasi, R. H. Samson, S. S. Berman, and P. I. Investigators. 2006. Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43(4):742-750. Corvinus, F. M., C. Orth, R. Moriggl, S. A. Tsareva, S. Wagner, E. B. Pfitzner, D. Baus, R. Kaufmann, L. A. Huber, K. Zatloukal, H. Beug, P. Ohlschager, A. Schutz, K. J. Halbhuber, and K. Friedrich. 2005. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7(6):545-555. Cravatt, B. F., A. T. Wright, and J. W. Kozarich. 2008. Activity-based protein profiling: From enzyme chemistry. Annu Rev Biochem 77:383-414. D'Acquisto, F., A. Ialenti, A. Ianaro, R. Di Vaio, and R. Carnuccio. 2000. Local administration of transcription factor decoy oligonucleotides to nuclear factor-kappa B prevents carrageenin-induced inflammation in rat hind paw. Gene Therapy 7(20):1731-1737. Dajee, M., T. Muchamuel, B. Schryver, A. Oo, J. Alleman-Sposeto, C. G. De Vry, S. Prasad, D. Ruhrmund, R. Shyamsundar, D. Mutnick, K. Mai, T. Le, C. Parham, J. Zhang, L. Komuves, T. Colby, S. Hudak, L. M. McEvoy, and R. O. Ehrhardt. 2006. Blockade of experimental atopic dermatitis via topical NF-kappa B decoy oligonucleotide. J Invest Dermatol 126(8):1792-1803. Darnell, J. E. 2002. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740-749. Darnell, J. E., I. M. Kerr, and G. R. Stark. 1994. Jak-Stat Pathways and Transcriptional Activation in Response to Ifns and Other Extracellular Signaling Proteins. Science 264(5164):1415-1421. Das, M., D. Mishra, P. Dhak, S. Gupta, T. K. Maiti, A. Basak, and P. Pramanik. 2009. Biofunctionalized, Phosphonate-Grafted, Ultrasmall Iron Oxide Nanoparticles for Combined Targeted Cancer Therapy and Multimodal Imaging. Small 5(24):2883-2893. Dassie, J. P., X. Y. Liu, G. S. Thomas, R. M. Whitaker, K. W. Thiel, K. R. Stockdale, D. K. Meyerholz, A. P. McCaffrey, J. O. McNamara, and P. H. Giangrande. 2009. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27(9):839-U895. Davis, M. E. 2009. The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic. Mol Pharmaceut 6(3):659-668. De Vry, C. G., S. Prasad, L. Komuves, C. Lorenzana, C. Parham, T. Le, S. Adda, J. Hoffman, N. Kahoud, R. Garlapati, R. Shyamsundar, K. Mai, J. Zhang, T. Muchamuel, M. Dajee, B. Schryver, L. M. McEvoy, and R. O. Ehrhardt. 2007. Non-viral delivery of nuclear factor-kappa B decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 56(4):524-533. Derenzini, M., V. Sirri, D. Trere, and R. L. Ochs. 1995. The Quantity of Nucleolar Proteins Nucleolin and Protein B23 Is Related to Cell Doubling Time in Human Cancer-Cells. Lab Invest 73(4):497-502. Desmet, C., P. Gosset, B. Pajak, D. Cataldo, M. Bentires-Alj, P. Lekeux, and F. Bureau. 2004. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 173(9):5766-5775. Dhar, S., F. X. Gu, R. Langer, O. C. Farokhzad, and S. J. Lippard. 2008. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. P Natl Acad Sci USA 105(45):17356-17361. Ewing, B. and P. Green. 1998. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 8(3):186-194. Ewing, B., L. Hillier, M. C. Wendl, and P. Green. 1998. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8(3):175-185. Fang, X. H., J. J. Li, and W. H. Tan. 2000. Using molecular beacons to probe molecular interactions between lactate dehydrogenase and single-stranded DNA. Anal Chem 72(14):3280-3285. Farin, K., S. Schokoroy, R. Haklai, I. Cohen-Or, G. Elad-Sfadia, M. E. Reyes-Reyes, P. J. Bates, A. D. Cox, Y. Kloog, and R. Pinkas-Kramarski. 2011. Oncogenic Synergism between ErbB1, Nucleolin, and Mutant Ras. Cancer Res 71(6):2140-2151. Ferrari, M. 2005. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 5(3):161-171. Fichtner-Feigl, S., I. J. Fuss, J. C. Preiss, W. Strober, and A. Kitani. 2005. Treatment of murine Th1-and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. Journal of Clinical Investigation 115(11):3057-3071. Frank, D. A., S. Mahajan, and J. Ritz. 1997. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT)1 and STAT3 constitutively phosphorylated on serine residues. Journal of Clinical Investigation 100(12):3140-3148. Fried, M. and D. M. Crothers. 1981. Equilibria and Kinetics of Lac Repressor-Operator Interactions by Polyacrylamide-Gel Electrophoresis. Nucleic Acids Res 9(23):6505-6525. Galas, D. J. and A. Schmitz. 1978. DNAse footprinting: a simple method for the detection of protein-DNA binding specificity. Nucleic Acids Res 5(9):3157-3170. Gao, C., A. Kozlowska, S. Nechaev, H. Q. Li, Q. F. Zhang, D. M. S. Hossain, C. M. Kowolik, P. Chu, P. Swiderski, D. J. Diamond, S. K. Pal, A. Raubitschek, and M. Kortylewski. 2013. TLR9 Signaling in the Tumor Microenvironment Initiates Cancer Recurrence after Radiotherapy. Cancer Res 73(24):7211-7221. Gao, H. H., J. N. Xiao, Q. Sun, H. X. Lin, Y. L. Bai, L. Yang, B. F. Yang, H. Z. Wang, and Z. G. Wang. 2006. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol 70(5):1621-1629. Gao, J. H., H. W. Gu, and B. Xu. 2009. Multifunctional Magnetic Nanoparticles: Design, Synthesis, and Biomedical Applications. Accounts Chem Res 42(8):1097-1107. Garner, M. M. and A. Revzin. 1981. A Gel-Electrophoresis Method for Quantifying the Binding of Proteins to Specific DNA Regions - Application to Components of the Escherichia-Coli Lactose Operon Regulatory System. Nucleic Acids Res 9(13):3047-3060. Gazi, I. F., D. T. Boumpas, D. P. Mikhailidis, and E. S. Ganotakis. 2007. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 25(1):102-111. Gibbs, C. P., V. G. Kukekov, J. D. Reith, O. Tchigrinova, O. N. Suslov, E. W. Scott, S. C. Ghivizzani, T. N. Ignatova, and D. A. Steindler. 2005. Stem-like cells in bone sarcomas: Implications for tumorigenesis. Neoplasia 7(11):967-976. Gill, J. S., X. Zhu, M. J. Moore, L. Lu, M. J. Yaszemski, and A. J. Windebank. 2002. Effects of NFκB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 23(13):2773-2781. Gokulrangan, G., J. R. Unruh, D. F. Holub, B. Ingram, C. K. Johnson, and G. S. Wilson. 2005. DNA aptamer-based bioanalysis of IgE by fluorescence anisotropy. Anal Chem 77(7):1963-1970. Gottesman, M. M., T. Fojo, and S. E. Bates. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2(1):48-58. Guerra-Vladusic, F. K., G. Scott, V. Weaver, E. A. Vladusic, M. S. Tsai, C. C. Benz, and R. Lupu. 1999. Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. Int J Oncol 15(5):883-892. Gullotti, E. and Y. Yeo. 2009. Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery. Mol Pharmaceut 6(4):1041-1051. Hamaguchi, N., A. Ellington, and M. Stanton. 2001. Aptamer beacons for the direct detection of proteins. Anal Biochem 294(2):126-131. Harimaya, K., K. Tanaka, Y. Matsumoto, H. Sato, S. Matsuda, and Y. Iwamoto. 2000. Antioxidants inhibit TNF alpha-induced motility and invasion of human osteosarcoma cells: Possible involvement of NF kappa B activation. Clin Exp Metastas 18(2):121-129. Hazan-Halevy, I., D. Harris, Z. M. Liu, J. Liu, P. Li, X. M. Chen, S. Shanker, A. Ferrajoli, M. J. Keating, and Z. Estrov. 2010. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115(14):2852-2863. Hellsten, R., M. Johansson, A. Dahlman, O. Sterner, and A. Bjartell. 2011. Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells. Plos One 6(7). Hermann, T. and D. J. Patel. 2000. Biochemistry - Adaptive recognition by nucleic acid aptamers. Science 287(5454):820-825. Heyduk, E., E. Knoll, and T. Heyduk. 2003. Molecular beacons for detecting DNA binding proteins: mechanism of action. Anal Biochem 316(1):1-10. Hicke, B. J. and A. W. Stephens. 2000. Escort aptamers: a delivery service for diagnosis and therapy. Journal of Clinical Investigation 106(8):923-928. Hicke, B. J., A. W. Stephens, T. Gould, Y. F. Chang, C. K. Lynott, J. Heil, S. Borkowski, C. S. Hilger, G. Cook, S. Warren, and P. G. Schmidt. 2006. Tumor targeting by an aptamer. J Nucl Med 47(4):668-678. Hilvo, M., C. Denkert, L. Lehtinen, B. Muller, S. Brockmoller, T. Seppanen-Laakso, J. Budczies, E. Bucher, L. Yetukuri, S. Castillo, E. Berg, H. Nygren, M. Sysi-Aho, J. L. Griffin, O. Fiehn, S. Loibl, C. Richter-Ehrenstein, C. Radke, T. Hyotylainen, O. Kallioniemi, K. Iljin, and M. Oresic. 2011. Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression. Cancer Res 71(9):3236-3245. Hobbs, S. K., W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain. 1998. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. P Natl Acad Sci USA 95(8):4607-4612. Holschermann, H., T. H. W. Stadlbauer, A. H. Wagner, H. Fingerhuth, H. Muth, S. Rong, F. Guler, H. Tillmanns, and M. Hecker. 2006. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res 71(3):527-536. Hong, R. L., C. J. Huang, Y. L. Tseng, V. F. Pang, S. T. Chen, J. J. Liu, and F. H. Chang. 1999. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clin Cancer Res 5(11):3645-3652. Hovanessian, A. G., C. Soundaramourty, D. El Khoury, I. Nondier, J. Svab, and B. Krust. 2010. Surface Expressed Nucleolin Is Constantly Induced in Tumor Cells to Mediate Calcium-Dependent Ligand Internalization. Plos One 5(12). Huang, C. C., Y. F. Huang, Z. H. Cao, W. H. Tan, and H. T. Chang. 2005. Aptamer-modified gold nanoparticles for colorimetric determination of platelet-derived growth factors and their receptors. Anal Chem 77(17):5735-5741. Huckel, M., U. Schurigt, A. H. Wagner, R. Stockigt, P. K. Petrow, K. Thoss, M. Gajda, S. Henzgen, M. Hecker, and R. Brauer. 2006. Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1). Arthritis Res Ther 8(1). Hwang, D. W., H. Y. Ko, J. H. Lee, H. Kang, S. H. Ryu, I. C. Song, D. S. Lee, and S. Kim. 2010. A Nucleolin-Targeted Multimodal Nanoparticle Imaging Probe for Tracking Cancer Cells Using an Aptamer. J Nucl Med 51(1):98-105. Ihle, J. N. 2001. The Stat family in cytokine signaling. Curr Opin Cell Biol 13(2):211-217. Jalalian, S. H., S. M. Taghdisi, N. S. Hamedani, S. A. M. Kalat, P. Lavaee, M. ZandKarimi, N. Ghows, M. R. Jaafari, S. Naghibi, N. M. Danesh, M. Ramezani, and K. Abnous. 2013. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci 50(2):191-197. Jantz, D. and J. M. Berg. 2002. Binding assays get into the groove. Nat Biotechnol 20(2):126-127. Kanai, M., Y. Konda, T. Nakajaima, Y. Izumi, N. Kanda, A. Nanakin, Y. Kubohara, and T. Chiba. 2003. Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene 22(4):548-554. Kawamura, I., R. Morishita, N. Tomita, E. Lacey, M. Aketa, S. Tsujimoto, T. Manda, M. Tomoi, I. Kida, J. Higaki, Y. Kaneda, K. Shimomura, and T. Ogihara. 1999. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Therapy 6(1):91-97. Kole, R., A. R. Krainer, and S. Altman. 2012. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nature Reviews Drug Discovery 11(2):125-140. Kontzias, A., A. Kotlyar, A. Laurence, P. Changelian, and J. J. O'Shea. 2012. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12(4):464-470. Kortylewski, M., P. Swiderski, A. Herrmann, L. Wang, C. Kowolik, M. Kujawski, H. Lee, A. Scuto, Y. Liu, C. M. Yang, J. H. Deng, H. S. Soifer, A. Raubitschek, S. Forman, J. J. Rossi, D. M. Pardoll, R. Jove, and H. Yu. 2009. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27(10):925-U988. Kroemer, G. 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3(6):614-620. Krown, S. E., D. W. Northfelt, D. Osoba, and J. S. Stewart. 2004. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 31(6):36-52. Lee, D. E., H. Koo, I. C. Sun, J. H. Ryu, K. Kim, and I. C. Kwon. 2012. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chemical Society Reviews 41(7):2656-2672. Lee, J. F., J. R. Hesselberth, L. A. Meyers, and A. D. Ellington. 2004. Aptamer database. Nucleic Acids Res 32:D95-D100. Lee, J. F., G. M. Stovall, and A. D. Ellington. 2006. Aptamer therapeutics advance. Current Opinion in Chemical Biology 10(3):282-289. Lee, S. J., B. S. Youn, J. W. Park, J. H. Niazi, Y. S. Kim, and M. B. Gu. 2008. ssDNA aptamer-based surface plasmon resonance biosensor for the detection of retinol binding protein 4 for the early diagnosis of type 2 diabetes. Anal Chem 80(8):2867-2873. Leong, P. L., G. A. Andrews, D. E. Johnson, K. F. Dyer, S. Xi, J. C. Mai, P. D. Robbins, S. Gadiparthi, N. A. Burke, S. F. Watkins, and J. R. Grandis. 2003a. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. P Natl Acad Sci USA 100(7):4138-4143. Leong, P. L., G. A. Andrews, D. E. Johnson, K. F. Dyer, S. C. Xi, J. C. Mai, P. D. Robbins, S. Gadiparthi, N. A. Burke, S. F. Watkins, and J. R. Grandis. 2003b. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. P Natl Acad Sci USA 100(7):4138-4143. Li, J., H. E. Fu, L. J. Wu, A. X. Zheng, G. N. Chen, and H. H. Yang. 2012. General Colorimetric Detection of Proteins and Small Molecules Based on Cyclic Enzymatic Signal Amplification and Hairpin Aptamer Probe. Anal Chem 84(12):5309-5315. Li, N., T. Larson, H. H. Nguyen, K. V. Sokolov, and A. D. Ellington. 2010. Directed evolution of gold nanoparticle delivery to cells. Chem Commun 46(3):392-394. Lim, E. K., Y. M. Huh, J. Yang, K. Lee, J. S. Suh, and S. Haam. 2011. pH-Triggered Drug-Releasing Magnetic Nanoparticles for Cancer Therapy Guided by Molecular Imaging by MRI. Adv Mater 23(21):2436-+. Lim, W. T., S. S. Leong, C. K. Toh, C. S. Ang, N. S. Wong, E. H. Tan, and B. Chowbay. 2009. A phase I pharmacokinetic study of a liposomal formulation of paclitaxel administered weekly to Asian patients with solid malignancies. J Clin Oncol 27(15). Lin, W., L. P. Zheng, Q. C. Zhuang, J. Y. Zhao, Z. Y. Cao, J. W. Zeng, S. Lin, W. Xu, and J. Peng. 2013. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway. Bmc Complem Altern M 13. Liu, J. W. and Y. Lu. 2006. Fast colorimetric sensing of adenosine and cocaine based on a general sensor design involving aptamers and nanoparticles. Angew Chem Int Edit 45(1):90-94. Liu, J. W., D. Mazumdar, and Y. Lu. 2006. A simple and sensitive 'dipstick' test in serum based on lateral flow separation of aptamer-linked nanostructures'. Angew Chem Int Edit 45(47):7955-7959. Liu, L., K. M. McBride, and N. C. Reich. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha 3. P Natl Acad Sci USA 102(23):8150-8155. Liu, P. P., J. Le, and M. Nian. 2001. Nuclear factor-kappa B decoy - Infiltrating the heart of the matter in inflammatory heart disease. Circ Res 89(10):850-852. Liu, Y., L. Q. Lv, W. Xiao, C. Gong, J. Yin, D. H. Wang, and H. Sheng. 2011. Leptin Activates STAT3 and ERK1/2 Pathways and Induces Endometrial Cancer Cell Proliferation. J Huazhong U Sci-Med 31(3):365-370. Lu, L. M., X. B. Zhang, R. M. Kong, B. Yang, and W. H. Tan. 2011. A Ligation-Triggered DNAzyme Cascade for Amplified Fluorescence Detection of Biological Small Molecules with Zero-Background Signal. J Am Chem Soc 133(30):11686-11691. Luo, J., N. L. Solimini, and S. J. Elledge. 2009. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. Cell 136(5):823-837. Lupold, S. E., B. J. Hicke, Y. Lin, and D. S. Coffey. 2012. Identification and Characterization of Nuclease-Stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-Specific Membrane Antigen (vol 62, pg 4029, 2002). Cancer Res 72(15):3887-3887. Luque, I. and C. Gelinas. 1997. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol 8(2):103-111. Lymperopoulos, K., R. Crawford, J. P. Torella, M. Heilemann, L. C. Hwang, S. J. Holden, and A. N. Kapanidis. 2010. Single-Molecule DNA Biosensors for Protein and Ligand Detection. Angew Chem Int Edit 49(7):1316-1320. Mahalanabis, M., J. Do, H. Almuayad, J. Y. Zhang, and C. M. Klapperich. 2011. An integrated disposable device for DNA extraction and helicase dependent amplification (vol 12, pg 353, 2010). Biomed Microdevices 13(3):599-602. Mishra, S., P. Webster, and M. E. Davis. 2004. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 83(3):97-111. Miyazaki, Y., T. Satoh, K. Nishioka, and H. Yokozeki. 2006. STAT-6-mediated control of P-selectin by substance P and interleukin-4 in human dermal endothelial cells. Am J Pathol 169(2):697-707. Morishita, R., G. H. Gibbons, M. Horiuchi, K. E. Ellison, M. Nakajima, L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau. 1995. A Gene-Therapy Strategy Using a Transcription Factor Decoy of the E2f Binding-Site Inhibits Smooth-Muscle Proliferation in-Vivo. P Natl Acad Sci USA 92(13):5855-5859. Mrozek, E., C. A. Rhoades, J. Allen, E. M. Hade, and C. L. Shapiro. 2005. Phase I trial of liposomal encapsulated doxorubicin (Myocet (TM) M; D-99) and weekly docetaxel in advanced breast cancer patients. Ann Oncol 16(7):1087-1093. Mullis, K., F. Faloona, S. Scharf, R. Saiki, G. Horn, and H. Erlich. 1986. Specific Enzymatic Amplification of DNA Invitro - the Polymerase Chain-Reaction. Cold Spring Harb Sym 51:263-273. Nakamura, H., M. Aoki, K. Tamai, M. Oishi, T. Ogihara, Y. Kaneda, and R. Morishita. 2002. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Therapy 9(18):1221-1229. Nam, J. M., C. S. Thaxton, and C. A. Mirkin. 2003. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301(5641):1884-1886. Niemeyer, C. M., M. Adler, B. Pignataro, S. Lenhert, S. Gao, L. F. Chi, H. Fuchs, and D. Blohm. 1999. Self-assembly of DNA-streptavidin nanostructures and their use as reagents in immuno-PCR. Nucleic Acids Res 27(23):4553-4561. Niemeyer, C. M., M. Adler, and R. Wacker. 2005. Lmmuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol 23(4):208-216. O'Brien, M. E. R., N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler, and C. B. C. S. Grp. 2004. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX (TM)/Doxil (R)) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440-449. Otsuji, T., N. Ogata, M. Uyama, Y. Kaneda, and R. Morishita. 1999. In vivo transfection of cis element 'decoy' against NFkB binding site choroidal neovascularization. Invest Ophth Vis Sci 40(4):S937-S937. Pan, D., S. D. Caruthers, G. Hu, A. Senpan, M. J. Scott, P. J. Gaffney, S. A. Wickline, and G. M. Lanza. 2008. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance Imaging of vascular targets. J Am Chem Soc 130(29):9186-+. Pancotti, F., L. Roncuzzi, M. Maggiolini, and A. Gasperi-Campani. 2012. Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal 24(7):1390-1397. Pastan, I., R. Hassan, D. J. FitzGerald, and R. J. Kreitman. 2006. Immunotoxin therapy of cancer. Nat Rev Cancer 6(7):559-565. Peer, D., J. M. Karp, S. Hong, O. C. FaroKHzad, R. Margalit, and R. Langer. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751-760. Peschansky, V. J., Z. C. Liang, and C. Wahlestedt. 2012. RNAi Joins the 'Singles Club'. Mol Ther 20(11):2010-2011. Petrelli, F., K. Borgonovo, and S. Barni. 2010. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmaco 11(8):1413-1432. Pollet, J., U. Strych, and R. C. Willson. 2012. A peroxidase-active aptazyme as an isothermally amplifiable label in an aptazyme-linked oligonucleotide assay for low-picomolar IgE detection. Analyst 137(24):5710-5712. Quarcoo, D., S. Weixler, D. Groneberg, R. Joachim, B. Ahrens, A. H. Wagner, M. Hecker, and E. Hamelmann. 2004. Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. J Allergy Clin Immun 114(2):288-295. Rane, S. G. and E. P. Reddy. 2000. Janus kinases: components of multiple signaling pathways. Oncogene 19(49):5662-5679. Rettig, G. R. and M. A. Behlke. 2012. Progress Toward In Vivo Use of siRNAs-II. Mol Ther 20(3):483-512. Romano, M. F., A. Lamberti, R. Bisogni, P. Tassone, D. Pagnini, G. Storti, L. Del Vecchio, M. C. Turco, and S. Venuta. 2000. Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides. Gene Therapy 7(14):1234-1237. Romberg, B., W. E. Hennink, and G. Storm. 2008. Sheddable coatings for long-circulating nanoparticles. Pharm Res 25(1):55-71. Saha, K., S. S. Agasti, C. Kim, X. N. Li, and V. M. Rotello. 2012. Gold Nanoparticles in Chemical and Biological Sensing. Chem Rev 112(5):2739-2779. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, and H. A. Erlich. 1988. Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA-Polymerase. Science 239(4839):487-491. Saiki, R. K., S. Scharf, F. Faloona, K. B. Mullis, G. T. Horn, H. A. Erlich, and N. Arnheim. 1985. Enzymatic Amplification of Beta-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle-Cell Anemia. Science 230(4732):1350-1354. Sano, S., K. S. Chan, S. Carbajal, J. Clifford, M. Peavey, K. Kiguchi, S. Itami, B. J. Nickoloff, and J. DiGiovanni. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11(1):43-49. Sano, T., C. L. Smith, and C. R. Cantor. 1992. Immuno-Pcr - Very Sensitive Antigen-Detection by Means of Specific Antibody-DNA Conjugates. Science 258(5079):120-122. Sarris, A. H., F. Hagemeister, J. Romaguera, M. A. Rodriguez, P. McLaughlin, A. M. Tsimberidou, L. J. Medeiros, B. Samuels, O. Pate, M. Oholendt, H. Kantarjian, C. Burge, and F. Cabanillas. 2000. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Ann Oncol 1 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78229 | - |
dc.description.abstract | 本研究旨在開發一系統性方法於提升圈套寡核苷酸 (decoy
oligodeoxynucleotide, dODN) 對於轉錄訊息傳遞活化子3 (signal transducer and activator of transcription 3, STAT3) 的親和力,並將此系統性方法之產物運用於癌細胞抑制,以及延伸發展成活化之轉錄因子的感測方法與靶向性診療系統。過度活化的STAT3 可導致癌細胞的抗凋亡表現與抗藥性,其過度表現的下游蛋白質在此過程扮演了重要的角色。以Bcl-xL 蛋白質為例,其已被證實會影響細胞凋亡機制並降低多柔比星 (doxorubicin, DOX) 抑制癌細胞的功效。為了阻礙過度活化的STAT3 之作用,目前廣泛使用的圈套寡核苷酸模仿了核酸中與轉錄因子結合的啟動子 (promoter) 序列,可抑制轉錄因子並進而促進癌細胞進入凋亡程序。事實上圈套寡核苷酸可以被視為一種細胞內核酸抗體,其透過結構(雙股螺旋)以及特定鹼基序列達到選擇性蛋白質結合。借鏡適體 (aptamer) 的發展概念,本研究的目標為藉由系統性方法重新設計STAT3 圈套寡核苷酸的鹼基序列,讓其擁有更高的轉錄因子親合力,進而更有效地抑制異常活化的轉錄因子。本研究所提出的系統性方法結合了網路伺服器運算 (PiDNA)、寡核苷酸親合力試驗以及寡核苷酸細胞抑制試驗。該系統性方法的產物 (命名為hpdODN-Pi) 較目前廣泛使用的序列具備 (1) 10%~29%的STAT3 親合力提升,(2) 1.7~2.3 倍的選擇性提升 (STAT3-to-STAT1),(3) 約20% 的抗凋亡蛋白質負調控能力提升,以及(4) 約20% 的癌細胞抑制效力提升。相較於hpdODN-Pi 成功抑制癌細胞,其對纖維母細胞(對照組,沒有STAT3 過度活化)則不具顯著作用,顯示hpdODN-Pi可選擇性抑制STAT3 過度活化之癌細胞。 基於hpdODN-Pi 的親合力特性,本研究提出一個運用hpdODN-Pi 與螢光分子形成之複合物 (complex of hpdODN-Pi and dye, 簡稱PiD) 感測活化之轉錄因子的方法(in situ)。當此複合物遭遇活化之轉錄因子時,嵌入於hpdODN-Pi 雙股序列中的螢光分子 (SYBR green, 或 Quinacrine) 便會因轉錄因子的結合競爭(轉錄因子對序列的親合力高於螢光分子)而自圈套寡核苷酸脫離,此導致的螢光訊號 變化便可用以定量感測活化的轉錄因子,感測線性區間為5 nM 到100 nM。直接給予活細胞PiD 時,因活化的轉錄因子觸發之螢光訊號變化亦可由螢光顯微鏡直接觀察,顯示PiD 具有類似細胞內蛋白質顯影的功能。 根據hpdODN-Pi 的高STAT3 親合力與PiD 的成果,本研究提出以 hpdODN-Pi 和DOX 形成之複合物 (DOX-intercalated hpdODN-Pi, 簡稱 DOXON)對STAT3 異常活化之癌細胞進行靶向性診療的概念與方法。靶向性診療系統需具備三個必要機制,包含辨識目標、發出訊號、以及觸發藥物作用。DOXON 以hpdODN-Pi 辨識活化之STAT3 蛋白質並與其進行結合,嵌入的DOX 因為結合競爭而被釋放至細胞質中,在488 nm 光激發下可發出590 nm 螢光訊號。因STAT3的核酸結合位被hpdODN-Pi 佔據,導致細胞的抗凋亡基因表現下降,而且被釋放 的DOX 進入細胞核並嵌入核酸中,促使細胞啟動凋亡機制。其中,由於hpdODN-Pi 的基因調節與DOX 的機轉可產生協同作用,所以複合物的癌細胞抑制效果大於各別的單獨抑制效果總合。此外,DOXON 只於STAT3 過度活化之細胞內產生作用(如MCF-7 和HepG2 細胞),反之則沒有效果(如心肌細胞和纖維母細胞),證實了DOXON 為一有效的靶向性診療系統。本研究的貢獻在於提出並驗證了圈套寡核苷酸可經由系統性方法重新設計以提高其親合力與選擇性,進而提升圈套寡核苷酸抑制癌細胞的功效。此外,本研究根據其親合力特性發展出的轉錄因子感測方法與靶向性診療系統,發掘出了圈套寡核苷酸的多功能性,讓其不限縮於疾病治療研究而可更進一步運用於感測和診療。上述的研究成果亦可望推廣至其它種類的轉錄因子,促進圈套寡核苷酸在治療、診斷以及診療的研究發展。 | zh_TW |
dc.description.abstract | This study designed and proved a process that enhances the potency of the decoy oligodeoxynucleotide (dODN) against the signal transducer and activator 3 (STAT3), which is kind of oncogenic transcription factor (TF) in adult human cell. Furthermore, we discovered the undisclosed potential of the potency-enhanced STAT3-dODN in the diagnostics and theranostics. The results point out that the dODN is not only a therapeutic agent, but also is worthwhile to be researched in the applications relative to the diagnostic, and theranostic use.
Over-activated STAT3 plays an important role in a variety of malignant tumour. It not only facilitates the cancer proliferation and metastasis, but also decrease the susceptibility of the cell to chemotherapeutic agents through over-expressed anti-apoptotic proteins (e.g. cyclin D1 and Bcl-xL). To inhibit the abnormal STAT3 protein, small molecule inhibitors have achieved considerable outcome. However, they are usually involved in many other pathway and hence cause the undesired side effect. Searching for a drug with high specificity, effectiveness, and low cytotoxicity become an important issue. To this end, the double-stranded oligodeoxynucleotide that mimics the c-fos promoter sequence binding to the transcription factor is generated to block the activity of STAT3. Although the STAT3-dODN has much higher specificity, its binding affinity is not high enough to be a potent drug. Referring to the research idea of aptamer, we propose the first hypothesis in this study: the c-fos derived STAT3-dODN can be mutated and selected based on the binding affinity to discover a new dODN with higher cancer cell inhibitory potency. In the first part of the study, we report an in silico and in vitro combined selection to quickly evolve a potent anti-STAT3 hairpin dODN (named hpdODN-Pi). On the basis of a protein-DNA interaction prediction web server (PiDNA) and the concept of aptamer selection, hpdODN-Pi is selected from a 109 dODN library within few days by performing (I) in silico library construction, (II) in silico selection, (III) in silico counter selection, (IV) in vitro affinity-based selection, and (V) in vitro function-based selection sequentially. Binding assays proved that hpdODN-Pi featured the best STAT3-binding affinity and STAT3-to-STAT1 selectivity among the dODNs reported to date. In the MCF-7 cell model, RT-qPCR confirmed that hpdODN-Pi effectively suppressed the downstream mRNAs of STAT3 without affecting STAT1-related expression after transfection. Accordingly, hpdODN-Pi showed twice higher cancer cell killing efficacy than the c-fos consensus dODN, and its enhanced apoptotic efficacy was confirmed by the Annexin V-PI (flow cytometry) and TUNEL (confocal microscopy) assays. In summary, STEP is a useful approach for rapidly identifying a potent TF-inhibitory dODN, and hpdODN-Pi can be further investigated for STAT3-related therapeutics. The overall result proved the proposed hypothesis. The dODN and aptamer are the only two nucleotides that able to bind to the protein. On the basis of the feature, the aptamer have been used in the diagnostic sensor in many researches. However, the sensor-relative approach of dODN has not been discussed yet. Therefore, we propose the second hypothesis in this study: the dODN can be used in sensing transcription factor protein based on its high binding affinity. In the second part of the study, we propose a dye-intercalated dODN system for detecting the oncogenic STAT3. This system is constructed with the hpdODN (the product from the first part of study) and the intercalated fluorescent dye. For in vitro STAT3 detection and intracellular STAT3 imaging, the signal comes from the release of intercalated dye due to the binding competition from STAT3. The fluorescence signal increases while the “signal-off” type of dye is used (e.g. SYBR green) and decrease while the “signal-on” type of molecule is used (e.g. Quinacrine). Either system show a detection range between 10 nM to 100 nM of protein. And also show the potential in cell imaging. Overall, the utility of hpdODN in protein sensing is proved. One inspiring result is observed in the hpdODN-Quinacrine complex treated MCF-7 cell. The complex treated cell shows a much lower viability compared to the cells that treated with only hpdODN or Quinacrine. This result suggests the possible synergistic effect of the drug-intercalated hpdODN complex. Hence, we propose the third hypothesis: the dODN can be used in developing a selective complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect. In the third part of the study, we prove the idea by tackling STAT3-associated cancer cell lines with our DOXON complex, which is composed of a hpdODN and a broad-spectrum anti-cancer drug DOX that is also a structure-sensitive fluorescent reporter. Before internalisation, DOXON remains non-dissociated and does not emit fluorescence. After internalisation mainly through the pinocytosis and specific recognition of over-activated STAT3, DOXON dissociates into therapeutic dODN for STAT3 binding and releases DOX for taking anti-cancer effect. In addition, free DOX emits fluorescence indicating the presence of over-activated STAT3. Since the disassembly of DOXON is caused by STAT3 binding competition, the complex is selective and will not affect the normal cells without STAT3 over-activation. Moreover, the disassembled dODN and DOX exert dual pathway intervention and yield a synergistic anti-cancer effect. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:46:55Z (GMT). No. of bitstreams: 1 ntu-104-F99631012-1.pdf: 25171639 bytes, checksum: 9fe737464a30d525a3e68b758ba6acf3 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 摘要 i
Abstract iii Table of Contents v List of Figures vii List of Tables xiii Frequent abbreviations xiv Chapter 1 Introduction 1 1.1 The “decoy” of the therapeutic oligonucleotides 2 1.2 Decoy oligodeoxynucleotide engineering 4 1.3 Decoy oligodeoxynucleotide in therapeutics 9 1.4 Oligodeoxynucleotide in diagnostics 16 1.5 Experimental considerations 20 1.6 Objectives 27 Chapter 2 Literature review 28 2.1 Decoy ODN against the STAT3 and its therapeutic application 28 2.1.1 STAT3 activation in cancer 28 2.1.2 Therapeutic nucleotide for STAT3 regulation 32 2.1.3 STAT3 decoy oligodeoxynucleotide 35 2.2 dODN in sensing application 40 2.2.1 oligonucleotide-based sensing system 40 2.2.2 protein sensing system with engineered sequence 42 2.2.3 diagnosis application of dODN 51 2.3 DOX-dODN in synergistic anti-cancer and theranostic application 54 2.3.1 Typical theranostic system 54 2.3.2 Dual pathway intervention 61 2.3.3 Intercalation drug loading 64 Chapter 3 Enhancing the potency of STAT3-dODN and use it in cancer cell therapy 69 3.1 Brief introduction 69 3.2 Experimental 72 3.3 Results and Discussion 76 Chapter 4 Potency enhanced dODN in protein sensing 112 4.1 Brief introduction 112 4.2 Experimental 115 4.3 Results and Discussion 118 Chapter 5 Potency enhanced dODN in theranostics 162 5.1 Brief introduction 162 5.2 Experimental 164 5.3 Results and Discussion 167 Conclusion 199 References 201 | |
dc.language.iso | en | |
dc.title | 抗STAT3 圈套寡核苷酸應用於癌細胞診療之研究 | zh_TW |
dc.title | On the Anti-STAT3 Decoy Oligonucleotides for Cancer Cell Theranostics | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳力騏,徐善慧,劉?睿,陳倩瑜,侯詠德 | |
dc.subject.keyword | 圈套寡核?酸,癌細胞,診療,轉錄因子, | zh_TW |
dc.subject.keyword | decoy oligonucleotide,cancer cell,theranostics,transcription factor, | en |
dc.relation.page | 218 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-05 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 生物產業機電工程學研究所 | zh_TW |
顯示於系所單位: | 生物機電工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-F99631012-1.pdf 目前未授權公開取用 | 24.58 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。